Dr. Herrera joined the Scientific Advisory Board of PharmaEngine in November 2008. He created Alain Oncology Consulting in November 2008 after heading for ten years the oncology business at Sanofi-Aventis where he was Vice President responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007). He contributed to the worldwide registration of two products: oxaliplatin (ELOXATIN®) and rasburicase (FASTURTEC®/ELITEK®) as well as the gastric and head & neck indications for docetaxel (TAXOTERE®). He received his MD from Pitié-Salpétrière Hospital, Faculty of Medicine, Paris, France.
Dr. Chan joined PharmaEngine in February 2016. He is a board certified medical oncologist. In addition to clinical practice, he has involved in several global clinical trials. He conducted two investigator initiated trials while he was at National Health Research Institutes, Taiwan. He received his Ph.D. at University of Minnesota, USA and MD at Chung Shan Medical University, Taichung, Taiwan.
Dr. de Gramont joined the Scientific Advisory Board of PharmaEngine since January 2012. He was trained at the Laboratory of Molecular and Cellular Biology, National Institutes of Health (NIH), USA. After returning to France, he became Chief Operating Officer & General Manager at AAREC Filia Research, Paris. Most recently, he was Head of the New Drugs Evaluation Laboratory, Lausanne University Hospital, Switzerland. His expertise is in the area of translational medicine in oncology. He received his Ph.D. in Cellular Biochemistry at Pierre et Marie Curie University, Paris, France.
Mr. Chang joined PharmaEngine in February 2003. He is a certified public accountant (CPA) in Taiwan. He worked at TTY Biopharm as the Director of Stock Affairs Department, and MasterLink Securities and Sampo Securities for many years majored in IPOs in Taiwan. He received his Master degree of Accounting from National Taiwan University, Taipei, Taiwan.
Mr. Wu joined PharmaEngine in July 2004. He majored in marketing and sales of oncology products at Novartis (Taiwan) and Kirin (Taiwan), responsible for Glivec®, Aredia®, G-CSF and EPO. Mr. Wu received his Bachelor degree in Pharmacy, Taipei Medical University, Taipei, Taiwan